Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine

Indication
Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC

Other upcoming events for IMRX

Phase 3 ReadoutPhase 3 Topline: A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine — IMRX Phase 3 Readout | BioSniper